Stock & Company Details
Bio-Techne Corp $TECH
Price:
N/A
N/A
157M
$11B
52 Week High:
N/A
10 Day Average Volume:
N/A
105.00
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
TECH technical indicators
Latest Bio-Techne Corp (TECH) indicator readings as of 2026-10-08.
TECH's 14-day RSI is 54.7, in neutral territory. ADX reads 34.7, indicating a trending market. MACD (12, 26, 9) is 0.12, above the zero line.
TECH backtested strategy results
How 4 rule-based strategies performed on Bio-Techne Corp (TECH) over recent history, last backtested 2026-09-09. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +3.2% | 36% | 11 | -33.8% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -48.3% | 19% | 32 | -74.5% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -47.0% | 30% | 30 | -51.7% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +2.7% | 55% | 22 | -46.6% |
Overview
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Finance Bot
Ask your questions
Start by typing a question below.
